Catalog No.
Product Name
Application
Product Information
Citations
-
HSP90 Inhibitor
KW-2478 hydrochloride is a potent HSP90 inhibitor with an IC50 value of 3.8 nM. It exhibits significant anti-proliferative effects by inducing apoptosis in chronic myeloid leukemia (CML) and liver cancer cells. KW-2478 hydrochloride disrupts the BCR/ABL and MAPK signaling pathways, resulting in elevated levels of p27 and p21, along with reduced cyclin B1 expression. Additionally, it downregulates STAT3 expression, making it a valuable tool for cancer research, particularly in the contexts of CML and liver malignancies. -
HSP90 Inhibitor
HSP90-IN-10 is a selective inhibitor of the heat shock protein 90 (HSP90) chaperone. It demonstrates significant antiproliferative activity against HCC1954 breast cancer cells, with an IC50 value of 6 µM, while sparing normal epithelial cells from growth inhibition. Additionally, HSP90-IN-10 promotes apoptosis, making it a valuable tool for research into cancer therapies targeting the HSP90 pathway. -
Hsp90 Inhibitor
CPUY201112 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting a Kd of 27 nM. This compound induces p53-mediated apoptosis in MCF-7 cells, leading to cell cycle arrest. CPUY201112 is a valuable tool for cancer research, particularly in studies focusing on apoptosis pathways and cell cycle regulation. -
HSP70 Inhibitor
PET-16 is a selective HSP70 inhibitor that targets an allosteric site in the substrate-binding domain. By hindering the ATP-ADP cycling of HSP70, PET-16 effectively disrupts chaperone activity and promotes apoptosis, particularly in multiple myeloma cells. This compound is valuable for research focused on cancer biology, apoptosis mechanisms, and the role of heat shock proteins in disease progression. -
Hsp90 Inhibitor
WK88-1 is a potent inhibitor of Heat Shock Protein 90 (Hsp90), which promotes the degradation of various oncogenic signaling proteins, including EGFR, ErbB2, and ErbB3. This compound effectively induces growth arrest and apoptosis in the Gefitinib-resistant H1975 cell line. WK88-1 is valuable for research applications focused on cancer biology, particularly in studies targeting Hsp90-dependent pathways in drug-resistant tumor models. -
HSP90 Inhibitor
17-Demethoxy-reblastatin is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 1.82 μM for yeast Hsp90 ATPase activity. This compound effectively inhibits the proliferation of cancer cell lines, including HepG2 and SMMC7721, while also reducing colony formation. Additionally, it induces apoptosis through mitochondrial and caspase-mediated pathways, making it a valuable reagent for cancer research and therapeutic investigations targeting Hsp90 activity. -
Hsp90/HDAC6 Inhibitor
HDAC6/HSP90-IN-2 is a dual inhibitor targeting both HDAC6 and Hsp90, exhibiting IC50 values of 105.7 nM and 61 nM, respectively. This compound demonstrates significant potential in cancer research, enabling the study of mechanisms involved in tumorigenesis and the development of novel therapeutic strategies. Its ability to modulate key cellular pathways associated with cancer progression makes it a valuable tool for investigating the role of HDAC6 and Hsp90 in various malignancies. -
Hsp90 Inhibitor
HSP90-IN-18 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 0.39 μM. This compound effectively disrupts Hsp90 function, making it valuable for research into viral infections, neurodegenerative diseases, and inflammatory conditions. Its capability to modulate Hsp90 activity provides a useful tool for studying the biological pathways influenced by this essential chaperone protein. -
Hsp90-Cdc37 PPI Inhibitor
Hsp90-Cdc37-IN-4 is a selective inhibitor of the Hsp90-Cdc37 protein-protein interaction (PPI). This compound disrupts the interaction by inhibiting casein kinase 2 (CK2), leading to reduced phosphorylation of Cdc37 at Serine 13. In cellular assays, Hsp90-Cdc37-IN-4 has been shown to induce G0/G1 cell cycle arrest and activate apoptotic pathways via the mitochondria. Additionally, it exhibits significant anti-breast cancer properties, making it a valuable tool in cancer research. -
HSP90 Inhibitor
HSP90-IN-13 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of 25.07 nM. This compound exhibits multi-target activity, affecting key proteins such as Epidermal Growth Factor Receptor (EGFR), Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), and Topoisomerase-2. HSP90-IN-13 promotes cell cycle arrest at the G2/M phase and induces apoptosis in MCF-7 cancer cells via a mitochondrial-mediated pathway, making it a valuable reagent for cancer research and therapeutic studies. -
HSP70 Ligand
HSP70 Ligand 1 serves as a ligand for the heat shock protein 70 (HSP70), facilitating the development of PROTAC molecules. This compound is instrumental in synthesizing PROTAC HSP70 Degrader-1, enabling targeted protein degradation studies. It is valuable for researchers investigating HSP70's role in cellular stress responses and therapeutic applications. -
Combined with Hsp90
AMP-PCP disodium is an ATP analogue that specifically targets the N-terminal domain of Hsp90, exhibiting a dissociation constant (Kd) of 3.8 μM. By binding to Hsp90, AMP-PCP disodium promotes the formation of its active homodimer, facilitating studies on protein folding and maturation. This reagent is valuable for research applications focusing on molecular chaperones and their roles in cellular stress responses. -
HSP Inhibitor
Apatorsen sodium is a 2'-methoxyethyl-modified antisense oligonucleotide targeting Hsp27. It effectively reduces Hsp27 mRNA and protein levels, disrupting stress-induced cytoprotective functions, promoting apoptosis, inhibiting tumor growth, and preventing metastasis. This compound is relevant for research applications in non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer. -
Hsp90-Cdc37 PPI Inhibitor
DDO-5936 is a potent inhibitor of the Hsp90-Cdc37 protein-protein interaction. This compound specifically disrupts the chaperone-client complex, leading to altered protein folding and degradation pathways. Its biological activity makes DDO-5936 a valuable tool for research applications focused on colorectal cancer and other related therapeutic areas. -
HSPA5 Inhibitor
HM03 is a selective inhibitor of HSPA5 (Heat Shock Protein 70kDa, also known as Bip or Grp78). This compound exhibits significant anticancer activity, making it a valuable tool for cancer research. It can be utilized to study the role of HSPA5 in tumor progression and therapeutic resistance, providing insights into potential treatment strategies targeting this chaperone protein. -
HSP Co-Inducer
Arimoclomol is an orally active co-inducer of heat shock proteins (HSP). It functions by enhancing Hsp expression, thereby providing protection to motor neurons through the modulation of protein aggregation and promoting the clearance of misfolded proteins via the proteasome-ubiquitin system. This compound is particularly relevant for research applications concerning Niemann-Pick disease type C, as it effectively crosses the blood-brain barrier, facilitating its therapeutic potential in neurological disorders. -
Hsp90 Inhibitor
Zelavespib hydrochloride is a potent inhibitor of the heat shock protein 90 (Hsp90), exhibiting an IC50 of 51 nM in MDA-MB-468 cancer cell lines. This compound disrupts Hsp90 function, leading to the degradation of client oncoproteins, thereby demonstrating significant potential in cancer research. Zelavespib is utilized in studies focused on the therapeutic targeting of Hsp90 for various malignancies. -
HSP Co-Inducer
Arimoclomol citrate is an orally active co-inducer of heat shock proteins (HSPs). It enhances the expression of HSPs, thereby protecting motor neurons by facilitating the clearance of misfolded proteins via the proteasome-ubiquitin system. This compound is particularly relevant for research applications concerning Niemann–Pick disease type C and studies of neurodegenerative disorders linked to protein aggregation. -
Hsp70 Inhibitor
YM-1 is an orally active inhibitor of the heat shock protein 70 (Hsp70). This compound has been shown to induce apoptosis in HeLa cells while also up-regulating key regulatory proteins such as p53 and p21. Its effects on cell viability and protein expression make YM-1 a valuable tool for studying the role of Hsp70 in cancer biology and therapeutic applications. -
PfHsp90 Inhibitor
Ursolic acid acetate is a triterpenoid compound that inhibits Plasmodium falciparum heat shock protein 90 (PfHsp90) with a binding affinity (KD) of 8.16 μM. It exhibits cytotoxic effects on KB cells, with an IC50 value of 8.4 μM. This compound is suitable for applications in tumor research and antimalarial studies, providing a valuable tool for investigating the role of heat shock proteins in disease mechanisms. -
HSP70 Allosteric Inhibitor
MAL3-101 is a potent allosteric inhibitor of the heat shock protein 70 (HSP70), primarily acting by inhibiting the ATPase activity of HSP70 through disruption of the Hsp40 co-chaperone interaction. This compound has demonstrated significant biological activity in cellular models, making it a valuable tool for investigating the role of HSP70 in muscle invasive bladder cancer (MIBC) research. Researchers can utilize MAL3-101 to explore therapeutic strategies targeting this molecular chaperone in cancer treatment. -
HSP90 Inhibitor
Icapamespib hydrochloride is a selective inhibitor of HSP90, targeting epichaperome assembly with slow dissociation kinetics. This compound effectively disrupts disease-related protein interaction networks, reducing neurotoxic protein aggregation and hindering tumor cell survival signals. Icapamespib hydrochloride is valuable in research focused on neurodegenerative diseases, including Alzheimer's disease, along with various cancers, such as glioblastoma and metastatic breast cancer. -
HSP90 Inhibitor
Icapamespib is a selective inhibitor of HSP90 that effectively disrupts epichaperome formation through non-covalent binding, exhibiting slow dissociation kinetics. This compound is capable of crossing the blood-brain barrier, facilitating the disassembly of abnormal protein interaction networks and reducing neurotoxic protein aggregation. Icapamespib demonstrates potential in research applications focused on neurodegenerative diseases, including Alzheimer’s disease, as well as various cancers such as glioblastoma and metastatic breast cancer. -
Hsp90 Inhibitor
SNX-0723 is a potent Hsp90 inhibitor that exhibits anti-Plasmodium activity. It demonstrates notable binding affinity for human Hsp90 and Plasmodium falciparum Hsp90, with inhibition constants (Kis) of 4.4 nM and 47 nM, respectively. Additionally, SNX-0723 effectively inhibits liver-stage Plasmodium berghei ANKA parasites, with an EC50 value of 3.3 μM, making it a valuable tool for research into malaria treatment and Hsp90-related biological processes. -
HSP60-derived Peptide
DiaPep277 is a 24 amino acid peptide derived from the HSP60 protein, specifically from positions 437-460. This peptide has been shown to halt the progression of β-cell destruction in NOD mice and exerts immune modulatory effects on diabetogenic T cells. DiaPep277 is primarily utilized in research studies focused on diabetes and immune response modulation, making it a valuable tool for understanding autoimmune mechanisms and potential therapeutic interventions. -
HSP70 ATPase Inhibitor
Displurigen (NSC375009) is an HSP70 ATPase inhibitor that specifically targets HSPA8, disrupting the pluripotency of human embryonic stem cells. This compound effectively inhibits the ATPase activity of HSP70 with an IC50 of 225 μM, making it a valuable tool for research in stem cell biology and differentiation processes. Its mechanism of action provides insights into cellular signaling pathways related to stem cell maintenance and development. -
HSP90β Inhibitor
KUNB31 is a selective inhibitor of HSP90β, exhibiting a binding affinity with a Kd value of 0.18 μM. This compound disrupts the function of the HSP90β protein, which is implicated in the maturation and stabilization of client proteins involved in cancer and other diseases. KUNB31 is valuable for research focused on cellular stress responses, protein homeostasis, and therapeutic strategies targeting protein chaperones. -
Hsp90 Inhibitor
Hsp90-IN-37 is a potent inhibitor of heat shock protein 90 (Hsp90), demonstrating a 69% reduction in enzymatic activity. This compound exhibits significant antitumor properties, making it a valuable tool in cancer research. Hsp90-IN-37 can be utilized to explore the role of Hsp90 in cancer cell survival and proliferation, supporting efforts to develop targeted therapies. -
Hsp90 Inhibitor
3-Phenyltoxoflavin is an Hsp90 inhibitor that interacts with the Hsp90-TPR2A complex, exhibiting a dissociation constant (Kd) of 585 nM. This compound demonstrates significant anti-cancer properties, making it a valuable tool for cancer research. Its ability to inhibit Hsp90 function provides insights into the molecular mechanisms of cancer cell growth and survival, supporting studies aimed at developing targeted therapies. -
HSP90 Inhibitor
Hsp90-IN-17 hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90), a chaperone protein involved in protein folding and stabilization. This compound demonstrates significant biological activity by disrupting the chaperoning function of HSP90, leading to the degradation of oncogenic client proteins. Hsp90-IN-17 is primarily used in research applications focused on proliferative diseases, including various cancer types and neurodegenerative disorders, providing insights into therapeutic strategies targeting HSP90. -
HSP Activator
Bimoclomol is an HSP activator that enhances the expression of heat shock proteins, playing a crucial role in cellular stress response. It demonstrates significant protective effects in cardiovascular tissues by promoting cytoprotection and anti-apoptotic mechanisms. Bimoclomol is utilized in research investigating its potential therapeutic applications in ischemic tissue damage and other stress-related conditions. -
HSP90 Inhibitor
HSP90-IN-23 is a potent inhibitor of heat shock protein 90 (HSP90) with an IC50 value of 9 nM. This compound effectively induces apoptosis in tumor cells and successfully arrests the cell cycle in the G0/G1 phase. HSP90-IN-23 is an invaluable tool for cancer research, facilitating the study of HSP90's role in tumorigenesis and potential therapeutic strategies. -
HSP70 Inhibitor
AP-4-139B is a potent inhibitor of HSP70, exhibiting an IC50 of 180 nM against human HSP70. Its mechanism involves direct binding to HSP70, leading to the inhibition of ATPase activity. By facilitating the phosphorylation of Beclin-1, AP-4-139B promotes autophagy. This compound has demonstrated significant antitumor activity in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma, making it a valuable tool for cancer research. -
Hsp70 Activator
SW02 is a potent Hsp70 activator that enhances ATPase activity with an EC50 of 150 μM. This compound induces the accumulation of total tau and phosphorylated tau (pTau), making it a valuable tool for studying tau pathologies. Its ability to modulate Hsp70 activity is of particular interest in neurodegenerative disease research. -
Hsp90 Inhibitor
HSP90-IN-22 is an inhibitor of heat shock protein 90 (Hsp90) that exhibits significant antiproliferative activity in cancer cells. The compound demonstrates IC50 values of 3.65 μM in MCF7 breast cancer cells and 2.71 μM in SKBr3 breast cancer cells. This compound is valuable for research into cancer cell biology and the therapeutic potential of Hsp90 inhibition in cancer treatment. -
Fluorescently-tethered Hsp90 Inhibitor
HS-27 is a fluorescently-tethered inhibitor targeting Heat Shock Protein 90 (Hsp90), facilitating the assessment of surface Hsp90 expression on intact tissue specimens. Comprising core elements of SNX-5422 linked through a PEG spacer to a fluorescein derivative, HS-27 selectively binds to ectopically expressed Hsp90. This reagent is particularly valuable in breast cancer research, providing a tool for applications involving visualization and treatment strategies. -
Hsp110/sGC Regulator
Hsp110/sGC-modulator-1 is a dual-target regulator that modulates Hsp110 and soluble guanylate cyclase (sGC) activities. This compound demonstrates significant inhibitory effects on cell malignancy and promotes vasodilation, making it valuable for cardiovascular research. Additionally, Hsp110/sGC-modulator-1 mitigates pulmonary vascular remodeling and right ventricular hypertrophy through the suppression of Hsp110, highlighting its potential in therapeutic applications for pulmonary hypertension and related disorders. -
Hsp27 Inhibitor
Apatorsen is a 2'-methoxyethyl-modified antisense oligonucleotide that functions as a Heat Shock Protein 27 (Hsp27) inhibitor. By reducing Hsp27 mRNA and protein levels, Apatorsen disrupts stress-induced cytoprotective mechanisms, promotes apoptosis, inhibits tumor growth, and prevents metastasis. This compound is particularly relevant for research focused on non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer. -
PROTAC Hsp90α Degrader
PROTAC Hsp90α degrader 1 is a selective degrader targeting the heat shock protein 90 alpha (Hsp90α) through the PROTAC (proteolysis targeting chimeras) mechanism. This compound exhibits significant cytotoxic activity against various breast cancer cell lines, including MDA-MB-231, MDA-MB-468, MCF-7, and MX-1, with IC50 values of 51.48 μM, 16.46 μM, 8.93 μM, and 11.95 μM, respectively. PROTAC Hsp90α degrader 1 is valuable for investigating the role of Hsp90α in oncogenesis and developing targeted therapies for breast cancer. -
HSP90 Inhibitor
Aminohexylgeldanamycin (AHGDM) is a potent inhibitor of HSP90, a chaperone protein essential for the proper folding and function of many oncoproteins. This compound exhibits significant antiangiogenic and antitumor activities, making it a valuable tool in cancer research. Its ability to disrupt HSP90 function highlights its potential in the study of tumor biology and therapeutic interventions targeting heat shock proteins. -
HSP90 Inhibitor
CH5015765 is a potent HSP90 inhibitor that targets the N-terminal ATP binding site with a dissociation constant of 3.4 nM. This compound demonstrates significant antiproliferative activity, exhibiting IC50 values of 0.46 μM in HCT116 colorectal cancer cells and 0.57 μM in NCI-N87 gastric cancer cells. CH5015765 is suitable for research applications focused on cancer biology and therapeutic development. -
HSP Activator
Feretoside is a phenolic compound derived from the bark of Eucommia ulmoides, functioning as a heat shock protein (HSP) activator. This compound demonstrates significant cytoprotective activities by enhancing cellular stress response mechanisms. Feretoside is primarily utilized in research applications aimed at studying cellular resilience, neuroprotection, and therapeutic strategies for stress-related disorders. -
HSP90 Inhibitor
HSP90-IN-27 is a potent inhibitor of the heat shock protein 90 (HSP90), which plays a critical role in protein folding and stabilization of client proteins involved in cancer progression. This compound effectively disrupts HSP90 function, leading to the degradation of oncogenic proteins and subsequent inhibition of tumor growth. HSP90-IN-27 is applicable in cancer research, particularly in studies focused on targeted therapies and the molecular chaperone network. -
Hsp60-Hsp10 Inhibitor
[Au(TPP)]Cl is an inhibitor of the Hsp60-Hsp10 complex, which plays a critical role in protein folding and cellular stress responses. This compound demonstrates significant anticancer activity by disrupting the refolding process of misfolded proteins, thereby promoting cell apoptosis in cancerous cells. [Au(TPP)]Cl is valuable for research applications targeting cancer therapy and understanding the molecular mechanisms of chaperone functions. -
Hsp90 Inhibitor
Onalespib lactate is a highly potent inhibitor of heat shock protein 90 (Hsp90) with a Kd of 0.71 nM, demonstrating the capability to cross the blood-brain barrier. This compound effectively inhibits tumor cell proliferation, survival, and migration, while reducing the expression of key signaling proteins such as EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, and P-S6. With its significant antitumor activity, Onalespib lactate is particularly relevant for research into non-small cell lung cancer (NSCLC). -
Hsp90 Modulator
Cemdomespib is a potent second-generation modulator of Hsp90, known for its high bioavailability. This compound has demonstrated the ability to enhance sensory function in models of diabetic peripheral neuropathy by inducing Hsp70 levels. Its neuroprotective effects are attributed to the activation of the heat shock response, making it a valuable tool for research into neurodegenerative conditions and related therapeutic interventions. -
p38/Hsp Activator
Iroxanadine sulfate is a dual activator of p38 kinase and heat shock protein (HSP), functioning as a vasculoprotector. This compound exhibits significant biological activity relevant to vascular health and has potential applications in the study of atherosclerosis and other vascular diseases. Researchers may utilize Iroxanadine sulfate to explore therapeutic strategies aimed at modulating p38 and HSP signaling pathways in various models of vascular pathology. -
HSP90 Inhibitor
HSP90-IN-11 is a potent inhibitor of HSP90, exhibiting strong inhibition of HSP90α activity. This compound demonstrates significant antiproliferative effects in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) cell lines, with IC50 values in the low double-digit nanomolar range. HSP90-IN-11 facilitates the rapid degradation of client proteins such as EGFR and Akt in NSCLC cells and induces a notable accumulation of sub-G1 phase cell populations, highlighting its potential for cancer research applications. -
HSP
p5 Ligand for DnaK and DnaJ is a nonapeptide that specifically targets the heat shock proteins DnaK and DnaJ. This ligand corresponds to the primary binding site of a 23-residue segment within the presequence of mitochondrial aspartate aminotransferase, demonstrating high affinity for these chaperones. Its biological activity supports research in cellular stress responses and protein folding mechanisms, making it valuable for studies on molecular chaperones and their roles in various cellular contexts. -
Hsp90 inhibitor
BX-2819 is a potent inhibitor of Heat Shock Protein 90 (Hsp90) with an IC50 value of 41 nM. This compound effectively inhibits the proliferation of various cancer cell lines and has demonstrated significant antitumor activity in vivo, notably reducing the growth of NCI-N87 and HT-29 tumors in nude mouse models. BX-2819 is a valuable tool for research into cancer biology and potential therapeutic strategies targeting Hsp90.
